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 CASE -REPORT
A 69 -year -old Caucasian female was sent to the emergency room 
by her general practitioner due to severe hypokalemia (1.7 mmol/L) 
detected in a routine evaluation.
Her medical history was remarkable only for a 20 -year history of 
hypertension and vertigo two years ago. Her medication included an 
association of perindopril, indapamide and amlodipine (10/2.5/10mg), 
omeprazole (20mg), lorazepam (1mg) and betahistine (24mg).
A family history of hypertension (mother, 6 siblings and two sons 
of 34 and 42 years of age) was present.
She has been experiencing in the previous months increasing 
hypertension, dry mouth, paresthesia in the lower limbs and weight 
loss (10 kg during the previous year). No changes in medication was 
ordered during that time.
In retrospect, it was noted that blood tests, performed three years 
as well as three months prior to admission already showed hypoka-
lemia (respectively, 3.1 mmol/L and 2.3 mmol/L). At that time point 
a prolonged QTc interval was also present in the electrocardiogram 
(EKG).
On admission to the emergency room, her blood pressure was 
very high, 216/111 mmHg; a systolic murmur was heard at left sternal 
border and minor hydrostatic peripheral edema was found.
An arterial blood gas sample showed metabolic alkalemia (pH 
7.507, PCO2 48.2 mmHg, PO2 78.3 mmHg, HCO3 - 37.3 mmol/L). Other 
laboratory testing revealed an increased serum creatinine of 1.2 mg/
dL (previously 0.8 mg/dL), urea 45 mg/dL, natremia (Na+) 142 mmol/L, 
hypokalemia (K+) of 2.01 mmol/L, chloride (Cl -) of 98 mmol/L, mag-
nesium of 2.1 mg/dL. Hemogram was normal (hemoglobin 13.3 g/dL, 
platelets 244x109/L) and LDH was 307 U/L. The urinary ionogram 
showed Na+ 109 mEq/L, K+ 19 mEq/L, Cl - 115 mEq/L. Thyroid function 
tests were normal. The EKG showed sinus rhythm with a prolonged 
QT associated with flattened T waves.
The patient was admitted to an intensive care unit and started on 
a continuous intravenous infusion of potassium chloride (15 mEq/h), 
supplemented with oral potassium chloride and spironolactone, 50 
mg daily. This was supplemented with magnesium sulfate during three 
days as approximately 50% of patients with hypokalemia also have 
concomitant magnesium deficiency. Although approximately 99% of 
the body’s total store of magnesium lies intracellular, a normal serum 
magnesium may grossly underestimate a true body deficit of 
magnesium, so magnesium replacement should be considered for 
patients with hypokalemia.1 Progressive normalization of serum K+ 
concentration as well as of EKG was noted.
Further investigation was pursued with blood tests and an abdomi-
nal computed tomography (CT), which was unremarkable except for 
a nodular lesion, measuring roughly 3 cm, in the right adrenal gland, 
that was suggestive of adenoma.
  WHAT IS THE MOST COMMON CAUSE  
OF SECONDARY HYPERTENSION?
Primary hypertension accounts for 90–95% of adult cases and may 
occur as a result of environmental or genetic causes. Secondary hyper-
tension, although rare, has multiple etiologies, making its correct 
investigation and classification more difficult. However, identifying 
the underlying cause makes achieving a cure more likely.
Every physician should be alert to the possibility of secondary 
hypertension. Clinical suspicion should be based on patient age at 
onset, presence of malignant or accelerated hypertension, and an 
acute rise in blood pressure from previously stable readings.
Our patient was a 67 -year -old female. The most common cause 
of secondary hypertension in this age group (>65 years) is renal artery 
stenosis and renal failure, secondary to atherosclerosis. However, this 
patient had had uncontrolled hypertension over the previous 10 years; 
therefore, her differential diagnosis could be broadened to include 
diagnoses more common to a younger age group (40 to 64 years). At 
that age, hyperaldosteronism, obstructive sleep apnea, Cushing’s 
syndrome and pheochromocytoma are more frequent. 2,3
From the clinical history, obstructive sleep apnea was excluded as 
the patient has no history of snoring, nocturne apneic episodes or 
daytime sleepiness. Pheochromocytoma was a weak hypothesis, as 
the patient had no suggestive clinical symptoms. Nevertheless, plas-
matic metanephrines were checked and found to be normal (normeta-
nephrines 78pg/mL, metanephrines 73pg/mL).
On physical examination, the patient had no signs of Cushing’s 
syndrome, such as buffalo hump, central obesity or moon facies. Fur-
ther laboratory investigation also showed normal 24 -hour urinary free 
cortisol (28 ug/24h), ACTH (13.3 pg/mL), morning salivary cortisol 
(5.38 nmol/L) and serum cortisol (12.5 μg/dL).
We excluded renal artery stenosis with a CT angiography. Consid-
eration for chronic renal failure was discarded since the patient had 
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previously normal serum creatinine, normal renal measurement, low 
urine albumin (3.7 mg/L). Moreover, the albumin to creatinine urinary 
ratio was also low: 14.6 mg/g.
Primary hyperaldosteronism (PA) seemed the most probable diag-
nosis, since the patient presented with hypokalemia, metabolic alka-
lemia and hypertension.
PA is the most common cause of secondary hypertension and con-
sists of an inappropriately elevated aldosterone production, in the 
setting of low plasma renin. The aldosterone, by inducing renal reab-
sorption of sodium at the distal convoluted tubule, increases secretion 
of K+ and hydrogen (H+) ions, causing hypernatremia, hypertension, 
hypokalemia and alkalosis. 2
The major forms of hyperaldosteronism are aldosterone -producing 
adenoma and bilateral idiopathic adrenal hyperplasia. Other entities 
are familial forms of primary aldosteronism, ectopic secretion of aldo-
sterone (more common in ovaries or kidneys) and pure aldosterone-
-producing adrenocortical carcinomas. This pathology is often under-
diagnosed and undertreated, which leads to cardiovascular morbidity 
and also mortality. This underlines the importance of an early diagnosis 
and treatment.4
The most recent indications for PA screening include patients with 
hypertension resistant to 3 conventional antihypertensive drugs; 
hypertension with hypokalemia (spontaneous or diuretic induced); 
hypertension and a family history of either early -onset hypertension 
or cerebrovascular accident at a young age (<40 years); hypertension 
and an adrenal tumor; controlled blood pressure on ≥4 antihyperten-
sive drugs; sustained blood pressure >150/100 mmHg, measured on 
3 different days; hypertension and sleep apnea, and all hypertensive 
first -degree relatives of patients with primary aldosteronism. Our 
patient meets at least 3 of these criteria. 3,4
Given the strong positive family history Liddle’s syndrome should 
be considered as a differential diagnosis However, our patient pre-
sented a high plasmatic aldosterone and normal urinary sodium which 
allowed us to exclude this diagnose.
The hypothesis of thrombotic microangiopathy was rejected since 
the patient had normal platelet count, normal hemoglobin and no 
raised LDH.
Based on ESC/ESH guidelines for the management of arterial hyper-
tension, hypertensive emergency is defined by the presence of organ 
damage. In this case report, even if asymptomatic, our patient pre-
sented with a CKD eGFR of 47ml/min/1.73m2 that should have raised 
suspicion of a hypertension emergency, and therefore should have 
undergone fundoscopy examination. 5
  WHY DOES THIS PATIENT HAVE HYPOKALEMIA 
AND METABOLIC ALKALOSIS?
As described above, in PA the high circulating levels of aldosterone 
will act in the distal convoluted tubule and cortical collecting duct of 
the kidney. This promote the expression of amiloride -sensitive 
epithelial sodium channels (ENaC) in the distal tubule and cortical 
collecting duct, resulting in sodium reabsorption to the intracellular 
compartment, which is then sent to the blood through interstitial fluid 
via Na+/K+ ATPase pumps on the basolateral surface of the cells, in 
trade of K+ that is secreted into urine via the apical renal outer medul-
lary K+ channel (ROMK) and causing the hypokalemia. Aldosterone 
also stimulates the urinary secretion of H+ via the H+ -ATPase in the 
intercalated cells of the cortical collecting tubules, causing the 
alkalosis.4
  WHAT IS THE MOST LIKELY CAUSE OF 
HYPOKALEMIA AND HYPERTENSION?
Hypokalemia is a common clinical problem that can result from 
decreased intake, increased translocation into the cells or, most often, 
increased losses of K+ in the urine or in the gastrointestinal tract.
Urinary K+ wasting is characteristic of any condition associated 
with primary hypersecretion of a mineralocorticoid, such as an 
aldosterone -producing adrenal adenoma. 6
Consequently, PA PA differential diagnoses include excess diuretic 
use including furosemide [inhibiting the Na+K+2Cl - cotransporter 
(NKCC2) in the thick ascending limb] and thiazides [inhibiting the Na+Cl - 
cotransporter (NCC) in the distal convoluted tubule]. These drugs, by 
inhibiting more proximal Na+ reabsorption, increase its delivery to the 
more distal connecting tubule and collecting duct where the ENaC-
-mediated electrogenic Na+ transport creates an electrical driving force 
for K+ secretion via the ROMK K+ channel. Further, they cause volume 
depletion and indirectly activate the renin -angiotensin -aldosterone 
system. A differential diagnosis with excessive excretion of nonreab-
sorbable anions, such as bicarbonate or beta -hydroxybutyrate, and 
renovascular disease, in which increased secretion of renin leads to 
enhanced aldosterone release, should also be considered. 4,6,7
In this clinical case, despite the patient taking a thiazide diuretic, 
urinary K+ loss induced by diuretics was not corroborated by the urinary 
ionogram, which showed urinary K+ in the normal range.
As mention above, PA is the most common cause of secondary 
hypertension, with a prevalence of 20% among patients with resistant 
hypertension. The presence of primary mineralocorticoid excess should 
be suspected in any patient with the triad of hypertension, unexplained 
hypokalemia, and metabolic alkalosis.
  IS IT POSSIBLE FOR A PATIENT TO HAVE 
NORMAL SERUM POTASSIUM AND PA? SHOULD 
WE TRUST ARR (PLASMA ALDOSTERONE TO 
RENIN RATIO) AS A MEANS OF DIAGNOSIS?
Hypokalemia is considered to be one of the major clinical features 
of PA. However, most patients with primary mineralocorticoid excess 
are normokalemic – only about 40% of patients with PA have hypoka-
lemia. This is likely related to earlier diagnosis, as more patients with 
hypertension are being screened with the plasma aldosterone to renin 
ratio (ARR), as a case -detection test for primary aldosteronism. 3
Silent hypokalemia – a sometimes fatal condition
194    Port J Nephrol Hypert 2019; 33(3): 192-195
For the diagnostic work -up, some experts suggest first identifying 
a low plasma renin activity (PRA<1ng/mL/h) and then requesting an 
aldosterone test (which must be increased >10 ng/dL). An ARR>20 is 
commonly used as the threshold for positive PA screening, with a 
sensitivity of 78% and a specificity of 83% in patients with resistant 
hypertension. The most important pitfall of PA screening is that some 
laboratories report PRA values as low as 0.1 ng/mL/h. Accordingly, an 
ARR>20 will be present even when the plasma aldosterone is as low 
as 2 ng/dL. Therefore, caution is necessary when interpreting an iso-
lated ARR, especially when PRA is <0.6 ng/mL/h. Another important 
consideration for a diagnosis of PA is that ARR and PRA must only be 
measured with a normal serum K+, as hypokalemia can inhibit aldo-
sterone production and cause a false negative test. 3
There are other pitfalls related to the screening of PA, such as 
antihypertensive medication (diuretics, angiotensin -converting 
enzyme inhibitors, and angiotensin receptor blockers can all cause 
false negative results), or misinterpretation of laboratory values (such 
as using direct renin concentration instead of PRA to calculate ARR). 
If the clinical suspicion is high, ARR should be repeated after withdraw-
ing these antihypertensive medications for at least two weeks. 3
We described a female patient with a 10 -year history of drug-
-resistant hypertension, metabolic alkalosis and severe hypokalemia, 
first identified in blood tests performed 3 years before the admission. 
Despite patient having an extremely low value of serum K+, no signifi-
cant clinical features such as muscle weakness, constipation or fatigue 
were noted. Moreover, she had no other major electrolyte imbalances, 
including excessive urinary K+ excretion or hypernatremia. Accordingly, 
we believe that this clinical scenario had a long evolution and some 
degree of adaptation. In fact, our patient presented with normal kali-
uresis, despite the use of indapamide and the PA. The authors cannot 
exclude a concomitant mechanism of K loss, namely gastrointestinal 
(covert vomiting), but there was no clinical reference to this aspect.
Patient’s blood tests showed low plasmatic renin activity (PRA; 
0.13 ng/mL/h), high plasmatic aldosterone concentration (PAC, 34 
ng/dL) and an ARR of 23, which is, in this clinical scenario, confirma-
tory of PA. It must be remembered that blood samples were collected 
during severe hypokalemia correction, but this should lead to lower 
than normal aldosterone activity (and not to these high levels).
As PA was suspected, the patient underwent an adrenal CT scan, 
which confirmed a right adrenal node of 3 cm diameter suggestive of 
adenoma. Our final diagnosis was PA.
It should be remembered that an isolated adrenal node in a CT 
scan is hardly a diagnosis of PA; the most commonly identified adrenal 
nodes are non -functional adrenal adenomas (sometimes referred to 
as “incidentalomas”), which may be present in up to 4% of the general 
population.
  DOES PRIMARY HYPERTENSION HAVE THE 
SAME IMPACT AS HYPERTENSION IN PA?
This 69 -year -old female patient had a 20 -year history of primary 
hypertension (age at diagnosis 50 years old), and, at least during the 
prior 10 years, had poorly controlled blood pressure and was medi-
cated with three different classes of antihypertensive drugs, including 
one diuretic. Accordingly, when an acute change in a chronic disease 
is noted, it should foster an effort to identify its trigger, to adjust the 
medication and to look for secondary causes of hypertension. Clinical 
inertia may have undesired clinical consequences on the patient’s 
morbidity and mortality.
In fact, evidence suggests that PA amplifies cardiovascular morbidity 
and mortality beyond primary hypertension, even after controlling 
for blood pressure values. Some studies have found that death from 
cardiovascular causes is more common among patients with PA com-
pared with matched control patients with primary hypertension. 3
Some pathophysiologic changes are seen in PA patients’ autopsies, 
such as fibrosis of the heart, adrenal glands, pancreas, and lungs. It 
has been found that PA is associated with vascular remodeling char-
acterized by a marked increase in arterial media/lumen ratio. These 
changes occur even in normotensive individuals. Stowasser et al. 
studied a population of normotensive patients with PA and found 
higher rates of concentric left ventricular hypertrophy and poor dia-
stolic function compared with age and sex matched normotensive 
control participants. Milliez et al. also found that, compared with 
patients with primary hypertension, patients with PA were more likely 
to have stroke, nonfatal myocardial infarction, or atrial fibrillation. 3
  WHAT ABOUT PATIENTS WHO SCREEN 
NEGATIVE FOR PA?
The prevalence of PA in patients with resistant hypertension might 
be as high as 20%. Moreover, some patients with negative screen 
tests for PA might still have a mild form of the disease, not meeting 
criteria for a formal diagnosis, yet possibly contributing to their hyper-
tension and long -time morbidity.
For this group of patients with resistant hypertension, spironolac-
tone is recommended, especially when a low K+ serum level is found. 
The PATHWAY -2 study demonstrated the superiority of spironolactone 
to bisoprolol or doxazosin, added to existing regimens, except in 
patients with the highest direct renin concentration. We recommend 
treatment with a mineralocorticoid receptor antagonist (MRA) for 
patients with resistant hypertension, who meet the criteria for PA 
screening and whose renin is normal or low but whose aldosterone 
is not high enough for a positive PA diagnosis. Close monitoring of 
electrolytes is essential when MRA drugs are used. 3
In this clinical case, our patient was discharged from hospital, 
receiving lisinopril 20mg, amlodipine 5mg and spironolactone 100mg. 
At that time she had achieved adequate blood pressure control and 
serum potassium normalization. An endocrinology appointment was 
arranged.
 CONCLUSION
We present a case of a 69 -year -old patient with a 10 -year history 
of drug -resistant hypertension. Although her relatively advanced age 
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was unusual for secondary hypertension, her clinical features posed 
a strong suspicion of PA. The fact that she was mostly asymptomatic 
was suggestive of a long -term evolution of PA and a delay in diagnosis. 
In fact, she had had known hypokalemia for at least three years.
In patients presenting with progressive resistant hypertension and 
electrolyte disturbances, screening for secondary hypertension should 
be performed independent of patient age.
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